本课题以颅内建立的恶性脑胶质母细胞瘤的裸鼠为动物模型，在构建一种对脑胶质母细胞瘤及骨髓间充质干细胞（Mesenchymal Stem Cell,MSC）具有高感染效率的新型诱导性溶瘤腺病毒载体Ad5/11-Ind-D24的基础上，采用对脑胶质母细胞瘤具有回归、靶向作用的MSC装载该新型诱导性溶瘤腺病毒载体进行恶性脑胶质母细胞瘤的实验治疗研究。在以上实验基础上，深入研究MSC装载携带外源治疗基因Arresten的诱导性溶瘤腺病毒载体对脑胶质母细胞瘤的治疗作用。该研究结果将为脑胶质母细胞瘤及其它肿瘤的有效治疗奠定基础。本课题是在已结题的国家自然科学基金基础上进一步深入研究，是在解决肿瘤基因治疗中的溶瘤腺病毒载体本身所存在缺陷的基础上，解决另外一个在恶性脑胶质母细胞瘤基因治疗中所存在的关键问题，即有效提高溶瘤腺病毒载体对肿瘤组织细胞的靶向性及病毒载体在肿瘤组织内的有效扩散与分布。

On the basis of the construction of a novel inducible adenoviral vector Ad5/11-Ind-D24, the experimental study was carried out in the animal model of nude mice bearing the intracranial glioblastoma xenograft using Ad5/11-Ind-D24 virus-loaded mesenchymal stem cell (MSC) that has an ability to target and home to glioblastoma. Then the therapeutic effect of Ad5/11-Ind-D24 carrying a therapeutic gene arresten for glioblastoma will be further investigated. The results will lay a foundation for the therapy of glioblastoam and other tumors. The project is an intensive study on the basis of a finished project funded by NSFC, which will solve another key problem present in the gene therapy of glioblastoma by effectively improving the targeting of oncolytic adenovirus for tumors and its broad distribution inside tumors on the basis of solving the shortcomings of oncolytic adenoviral vector.